Drug trial halted for diabetic pain relief
NCT ID NCT05838755
Summary
This study tested an investigational drug, GSK3858279, to see if it could reduce chronic nerve pain in the hands and feet of adults with diabetes. About 150 participants were randomly assigned to receive either the drug or a placebo for 12 weeks to compare pain relief and safety. The trial was terminated early, and its results for reducing pain scores are not publicly available in this summary.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Anniston, Alabama, 36207, United States
-
GSK Investigational Site
Surprise, Arizona, 85378, United States
-
GSK Investigational Site
Cerritos, California, 90703, United States
-
GSK Investigational Site
Lomita, California, 90717, United States
-
GSK Investigational Site
Largo, Florida, 33777, United States
-
GSK Investigational Site
Miami, Florida, 33135, United States
-
GSK Investigational Site
Miami, Florida, 33175, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33401, United States
-
GSK Investigational Site
Decatur, Georgia, 30030, United States
-
GSK Investigational Site
Chicago, Illinois, 60611, United States
-
GSK Investigational Site
Waltham, Massachusetts, 02451, United States
-
GSK Investigational Site
Williamsville, New York, 14221, United States
-
GSK Investigational Site
Huntersville, North Carolina, 28078, United States
-
GSK Investigational Site
Lancaster, South Carolina, 29720, United States
-
GSK Investigational Site
Cypress, Texas, 77429, United States
-
GSK Investigational Site
DeSoto, Texas, 75154, United States
-
GSK Investigational Site
Houston, Texas, 77030, United States
-
GSK Investigational Site
McAllen, Texas, 78501, United States
-
GSK Investigational Site
Bellevue, Washington, 98007, United States
-
GSK Investigational Site
New Westminster, British Columbia, V3L 3W4, Canada
-
GSK Investigational Site
Vancouver, British Columbia, V5Y 3W2, Canada
-
GSK Investigational Site
Winnipeg, Manitoba, R3C 0N2, Canada
-
GSK Investigational Site
Toronto, Ontario, L6S 0C6, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2C4, Canada
-
GSK Investigational Site
Beijing, 100032, China
-
GSK Investigational Site
Guangzhou, 510000, China
-
GSK Investigational Site
Harbin, 150001, China
-
GSK Investigational Site
Luoyang, 471003, China
-
GSK Investigational Site
Shanghai, 200032, China
-
GSK Investigational Site
Wuhan, 430030, China
-
GSK Investigational Site
Yueyang, 414000, China
-
GSK Investigational Site
Corbeil-Essonnes, 91100, France
-
GSK Investigational Site
Mulhouse, 68100, France
-
GSK Investigational Site
Bad Homburg, 61348, Germany
-
GSK Investigational Site
Mainz, 55128, Germany
-
GSK Investigational Site
Münster, 48145, Germany
-
GSK Investigational Site
Wallerfing, 94574, Germany
-
GSK Investigational Site
Chiba, 260-0804, Japan
-
GSK Investigational Site
Fukuoka, 807-8556, Japan
-
GSK Investigational Site
Gunma, 370-3573, Japan
-
GSK Investigational Site
Hokkaido, 060-0061, Japan
-
GSK Investigational Site
Ibaraki, 300-0028, Japan
-
GSK Investigational Site
Kanagawa, 211-8533, Japan
-
GSK Investigational Site
Osaka, 565-0853, Japan
-
GSK Investigational Site
Tochigi, 321-0204, Japan
-
GSK Investigational Site
Tochigi, 321-0974, Japan
-
GSK Investigational Site
Tochigi, 322-8550, Japan
-
GSK Investigational Site
Tokyo, 103-0027, Japan
-
GSK Investigational Site
Tokyo, 104-0031, Japan
-
GSK Investigational Site
Tokyo, 143-0015, Japan
-
GSK Investigational Site
Tokyo, 160-0008, Japan
-
GSK Investigational Site
Częstochowa, 42-217, Poland
-
GSK Investigational Site
Gdynia, 81-338, Poland
-
GSK Investigational Site
Katowice, 40-081, Poland
-
GSK Investigational Site
Katowice, 40-282, Poland
-
GSK Investigational Site
Katowice, 40-648, Poland
-
GSK Investigational Site
Katowice, 40-749, Poland
-
GSK Investigational Site
Skorzewo, 60-185, Poland
-
GSK Investigational Site
Sochaczew, 96-500, Poland
-
GSK Investigational Site
Warsaw, 02-117, Poland
-
GSK Investigational Site
Cape Town, 7530, South Africa
-
GSK Investigational Site
Johannesburg, 2196, South Africa
-
GSK Investigational Site
KwaDukuza, 4450, South Africa
-
GSK Investigational Site
Pretoria, 0184, South Africa
-
GSK Investigational Site
Somerset West, 7130, South Africa
-
GSK Investigational Site
Bucheon-si, 422711, South Korea
-
GSK Investigational Site
Daejeon, 35233, South Korea
-
GSK Investigational Site
Seoul, 120-752, South Korea
-
GSK Investigational Site
Seoul, 136-705, South Korea
-
GSK Investigational Site
Seoul, 137-701, South Korea
-
GSK Investigational Site
Seoul, South Korea
-
GSK Investigational Site
A Coruña, 15006, Spain
-
GSK Investigational Site
Barcelona, 08023, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
-
GSK Investigational Site
Palma de Mallorca, 07120, Spain
-
GSK Investigational Site
San SebastiAn de Los Rey, 28702, Spain
-
GSK Investigational Site
Torrevieja Alicante, 3186, Spain
-
GSK Investigational Site
Cannock, WS11 0BN, United Kingdom
-
GSK Investigational Site
Liverpool, L9 7AL, United Kingdom
-
GSK Investigational Site
Teesside, TS17 6EW, United Kingdom
-
GSK Investigational Site
West Yorkshire, LS10 1DU, United Kingdom
Conditions
Explore the condition pages connected to this study.